Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Patrick Naumann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9814-2151; OpenAlex author ID A5078379741. Sources: OpenAlex.

Their work

Papers
18 (first author 7, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 4 papers · 2020: 3 papers · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 18

  1. Carbon ion radiotherapy for non-metastatic pancreatic cancer: final results of the prospective phase 2 PACK-study (NCT04194268). First author DOI 10.1016/j.radonc.2026.111836↗
  2. Carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer. Last author DOI 10.1007/s00066-021-01827-9↗
  3. Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial. Co-author DOI 10.1016/j.ctro.2022.03.003↗
  4. Effectiveness of Carbon Ion Radiation in Locally Advanced Pancreatic Cancer. First author DOI 10.3389/fonc.2021.708884↗
  5. Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer. Last author DOI 10.3390/cancers13040796↗
  6. Carbon ion radiotherapy in pancreatic cancer: A review of clinical data. Last author DOI 10.1016/j.radonc.2020.05.012↗
  7. Radiographic Response of Vessel Involvement and Resectability After Neoadjuvant Chemoradiation in Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000746↗
  8. Carbon ion radiotherapy as definitive treatment in non-metastasized pancreatic cancer: study protocol of the prospective phase II PACK-study. First author DOI 10.1186/s12885-020-07434-8↗
  9. Comparing the effectiveness and efficiency of various gating approaches for PBS proton therapy of pancreatic cancer using 4D-MRI datasets. First author DOI 10.1088/1361-6560/ab1175↗
  10. 4DMRI-based investigation on the interplay effect for pencil beam scanning proton therapy of pancreatic cancer patients. Co-author DOI 10.1186/s13014-019-1231-2↗
  11. Continued Weight Loss and Sarcopenia Predict Poor Outcomes in Locally Advanced Pancreatic Cancer Treated with Chemoradiation. Co-author DOI 10.3390/cancers11050709↗
  12. Cachectic Body Composition and Inflammatory Markers Portend a Poor Prognosis in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation. Co-author DOI 10.3390/cancers11111655↗
  13. 4D dose calculation for pencil beam scanning proton therapy of pancreatic cancer using repeated 4DMRI datasets. First author DOI 10.1088/1361-6560/aad43f↗
  14. Sulforaphane enhances irradiation effects in terms of perturbed cell cycle progression and increased DNA damage in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0180940↗
  15. Phytotherapeutics Oridonin and Ponicidin show Additive Effects Combined with Irradiation in Pancreatic Cancer in Vitro. First author DOI 10.1515/raon-2017-0048↗
  16. Worst case optimization for interfractional motion mitigation in carbon ion therapy of pancreatic cancer. First author DOI 10.1186/s13014-016-0705-8↗
  17. Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer. Co-author DOI 10.1245/s10434-014-3607-8↗
  18. Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer. Co-author DOI 10.1007/s00066-013-0393-3↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jürgen Debus · 13 shared papers, 2013–2026 · strength 1.53
  2. Jakob Liermann · 11 shared papers, 2017–2026 · strength 1.51
  3. Klaus K Herfarth · 6 shared papers, 2020–2026 · strength 0.94
  4. Edgar Ben‐Josef · 3 shared papers, 2020–2022 · strength 0.42
  5. Thilo Hackert · 3 shared papers, 2019–2020 · strength 0.34
  6. Manuel Röhrich · 2 shared papers, 2021–2026 · strength 0.34
  7. Stephanie Elisabeth Combs · 4 shared papers, 2013–2019 · strength 0.31
  8. A. Pfaffenberger · 3 shared papers, 2018–2019 · strength 0.26
  9. Kai Dolde · 3 shared papers, 2018–2019 · strength 0.26
  10. Ye Zhang · 3 shared papers, 2018–2019 · strength 0.26
  11. Christoph Michalski · 1 shared paper, 2026 · strength 0.23
  12. Andrea Mairani · 1 shared paper, 2026 · strength 0.23
  13. Semi Harrabi · 1 shared paper, 2026 · strength 0.23
  14. Christoph Springfeld · 1 shared paper, 2026 · strength 0.23
  15. Filipa Baltazar · 1 shared paper, 2026 · strength 0.23
  16. Robert C Krempien · 1 shared paper, 2022 · strength 0.19
  17. Juergen Debus · 1 shared paper, 2022 · strength 0.19
  18. Stephanie Elisabeth Combs · 2 shared papers, 2017 · strength 0.15
  19. Franco Fortunato · 2 shared papers, 2017 · strength 0.15
  20. Makoto Shinoto · 1 shared paper, 2020 · strength 0.13
  21. Klaus Hermann Maier-Hein · 1 shared paper, 2020 · strength 0.12
  22. Frederik Lars Giesel · 1 shared paper, 2021 · strength 0.11
  23. Daniel Habermehl · 2 shared papers, 2013–2014 · strength 0.09
  24. Mark Bangert · 1 shared paper, 2016 · strength 0.07
  25. Julian Steitz · 1 shared paper, 2016 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.